Company
Headquarters: Hulin, China
Employees: 3,321
CN¥11.69 Billion
CNY as of July 1, 2025
US$1.63 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥2.06 B |
| EBITDA | CN¥1.01 B |
| Gross Profit TTM | CN¥1.07 B |
| Profit Margin | 10.71% |
| Operating Margin | 27.54% |
| Quarterly Revenue Growth | -58.00% |
Heilongjiang ZBD Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603567 wb_incandescent